Madrigal Licenses Arrowhead Drug Candidate for MASH
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) licensed a clinical-stage gene-silencing therapy from Arrowhead Pharmaceuticals to expand its pipeline of treatments for metabolic dysfunction-associated steatohepatitis, or MASH, including patients with …
Madrigal Licenses Arrowhead Drug Candidate for MASH Read More